Vident Advisory’s Madrigal Pharmaceuticals MDGL Stock Holding History

Vident Advisory’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$261K	Buy	487 +68	+16%	+$34.8K	﹤0.01%	1657
2026 Q1	$219K	Buy	+419	New	+$200K	﹤0.01%	1651

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vident Advisory's MDGL Position: Q2 2026 in Review

Vident Advisory increased its Madrigal Pharmaceuticals (MDGL) stake by 16% in Q2 2026, buying an estimated $34.8K and bringing the position to 487 shares worth $261K. The position accounts for ﹤0.01% of the portfolio, ranked #1657.

Vident Advisory first reported a position in MDGL in Q1 2026 and has held it in 2 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Vident Advisory held 487 shares of Madrigal Pharmaceuticals worth $261K as of Q2 2026.
Vident Advisory bought 68 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $34.8K.
Madrigal Pharmaceuticals made up ﹤0.01% of Vident Advisory's portfolio in Q2 2026, its #1657 holding.
Vident Advisory first reported a position in Madrigal Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.